Prometrium Cost vs Alternatives: Micronized Progesterone Compared to Every Progestogen in Class

What Is Prometrium and How Does It Work?

Prometrium is the brand name for oral micronized progesterone, a bioidentical hormone that is chemically identical to the progesterone produced by the ovarian corpus luteum. It binds directly to intracellular progesterone receptors in the endometrium, triggering secretory transformation of the uterine lining and suppressing estrogen-driven proliferation. Without adequate progestogen opposition in a woman with an intact uterus, unopposed estrogen raises endometrial cancer risk by three- to six-fold over five or more years of use, a finding confirmed across multiple observational cohorts 1.

Bioidentical vs Synthetic: Why the Distinction Matters Clinically

The word "bioidentical" is often misused in direct-to-consumer marketing, but it has a precise chemical meaning. Micronized progesterone shares the exact molecular structure of endogenous progesterone (C21H30O2). Synthetic progestins like medroxyprogesterone acetate (MPA) or norethindrone acetate are structurally different and bind not only to progesterone receptors but also to androgen, glucocorticoid, and mineralocorticoid receptors to varying degrees 2. Those off-target receptor interactions explain much of the difference in side-effect profiles, lipid effects, and possibly breast cancer risk between micronized progesterone and synthetic progestins.

Micronization and Oral Bioavailability

Raw progesterone has near-zero oral bioavailability because first-pass hepatic metabolism degrades it almost completely. Micronization reduces particle size to below 10 microns, dispersing the hormone in a peanut-oil base inside the capsule. This physical change raises peak plasma concentration (Cmax) to roughly 17 ng/mL after a 200 mg dose and produces a half-life of approximately 16 to 18 hours for the active metabolite allopregnanolone 3. Allopregnanolone itself acts on GABA-A receptors, which accounts for the sedation many patients notice within 60 to 90 minutes of the bedtime dose, and why nighttime dosing is standard.

How Prometrium Is Used in HRT: Approved Dosing

The FDA-approved indications for Prometrium are endometrial protection in postmenopausal women receiving conjugated estrogens and secondary amenorrhea 4.

Continuous-Combined Regimen

Dose: 100 mg orally at bedtime every night alongside daily estrogen. This regimen is preferred for women who are at least one year post-menopause and want to avoid monthly withdrawal bleeding. Breakthrough spotting is common in the first three to six months as the endometrium atrophies.

Cyclic (Sequential) Regimen

Dose: 200 mg orally at bedtime for 12 consecutive days per calendar month. A withdrawal bleed occurs in most women two to seven days after the last capsule. This approach mimics the natural luteal phase and is often used in peri-menopausal women who still have some endogenous cycle activity. The PEPI trial used this design and confirmed full endometrial protection at 12 days of cyclic use 5.

Off-Label Routes for Peanut-Allergic Patients

Women with peanut or peanut-oil allergy cannot use Prometrium capsules safely. Compounded progesterone in a non-peanut-oil base or vaginal progesterone gel (Crinone 4% or 8%) provides an alternative route. Vaginal administration delivers progesterone to the uterus via a direct cervico-uterine pathway, achieving endometrial tissue concentrations that are disproportionately high relative to serum levels, a phenomenon called the "first-uterine-pass effect" 6.

Prometrium Cost vs Every Major Alternative

Pricing below reflects January 2025 GoodRx cash-pay estimates for a 30-day supply at a standard HRT dose. Actual out-of-pocket costs vary by insurance, pharmacy, and location.

Brand Prometrium (AbbVie)

• 100 mg x 30 capsules: approximately $95 to $180
• 200 mg x 30 capsules: approximately $150 to $220 (cyclic use often requires fewer capsules per month)
• Insurance coverage: most commercial plans cover Prometrium at Tier 2 or Tier 3; Medicare Part D coverage varies by plan formulary.

Generic micronized progesterone (multiple manufacturers including Teva and Perrigo) costs $25 to $60 for 30 capsules of 100 mg and $40 to $80 for 200 mg capsules. The FDA considers the generic bioequivalent; switching from brand to generic is clinically safe for the vast majority of patients 7.

Medroxyprogesterone Acetate (Provera and Generics)

MPA generic tablets (2.5 mg, 5 mg, or 10 mg) cost $10 to $20 per month, making them by far the cheapest progestogen option. The 2.5 mg continuous dose or 10 mg cyclic dose for 12 days provides proven endometrial protection 5. The cost advantage is large. However, the Women's Health Initiative (WHI, N=16,608) showed that the conjugated equine estrogen plus MPA arm increased invasive breast cancer risk (hazard ratio 1.26, 95% CI 1.00 to 1.59) and coronary heart disease events compared with placebo 8. The estrogen-alone arm (women without a uterus, so no progestogen needed) did not show the same breast cancer signal, pointing to MPA as a contributor to that risk elevation.

Norethindrone Acetate (Aygestin)

Norethindrone acetate 5 mg tablets cost approximately $30 to $60 per month generic. At 0.5 mg to 1 mg daily, it provides continuous endometrial protection and is available as a combination pill with estradiol (Activella, generic). It carries androgenic activity that may worsen lipid profiles, acne, or libido in androgen-sensitive women 9. Some women prefer its lower cost over micronized progesterone when side effects are acceptable.

Levonorgestrel-Releasing IUD (Mirena 52 mg)

Mirena costs approximately $900 to $1,100 for the device plus $150 to $300 for insertion, totaling $1,050 to $1,400 upfront. Over five years of use the monthly cost averages $18 to $23, which is cheaper than any oral progestogen. The local levonorgestrel delivery suppresses endometrial proliferation with minimal systemic absorption (serum levonorgestrel approximately 150 to 200 pg/mL) 10. Several prospective studies and the British Menopause Society guidelines support Mirena as an effective progestogen component of HRT 11. Women who want systemic HRT without oral progestogen side effects or peanut-allergy concerns often find this route attractive.

Vaginal Progesterone Gel (Crinone 4% and 8%)

Crinone 4% gel (used off-label for HRT endometrial protection) and Crinone 8% (approved for ART luteal support) cost $200 to $350 per month without insurance, more expensive than oral micronized progesterone for the same protective outcome. Its primary advantage is avoidance of the first-pass sedative effect. Endometrial protection with vaginal progesterone gel in the HRT setting has been studied but the evidence base is smaller than for oral micronized progesterone 12.

Vaginal Progesterone Insert (Endometrin 100 mg)

Endometrin is FDA-approved for ART and costs $350 to $600 per cycle in that context. Using it off-label for HRT endometrial protection is uncommon and expensive. It is generally reserved for patients with specific contraindications to oral and gel formulations.

Compounded Progesterone (Topical Cream, Troches, Sublingual Drops)

Compounded progesterone in topical cream form is widely marketed but lacks evidence for consistent endometrial protection. A Cochrane review found insufficient data to conclude that topical progesterone cream reliably protects the endometrium in women using estrogen HRT 13. The NAMS 2022 Position Statement explicitly states that "custom-compounded bioidentical hormone therapy cannot be recommended as a first-line option because the data on safety and efficacy are insufficient" 14. Troches and sublingual drops may produce inconsistent serum levels. Compounded oral progesterone capsules in non-peanut-oil bases are a legitimate option for peanut-allergic patients, with pricing typically $30 to $80 per month at compounding pharmacies.

The PEPI Trial: The Foundational Evidence Base

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, published in JAMA in 1995 (N=875, randomized, 3-year follow-up), remains the most cited head-to-head comparison of progestogens in HRT 5. PEPI randomized women to five arms: placebo, conjugated equine estrogens (CEE) alone, CEE plus MPA continuous, CEE plus MPA cyclic, and CEE plus micronized progesterone cyclic.

Lipid Findings

CEE plus micronized progesterone produced the best HDL-cholesterol increase among all active arms, raising HDL by 5.6 mg/dL versus 1.6 mg/dL in the CEE plus continuous MPA arm. The trial authors concluded that "the CEE plus micronized progesterone regimen had the most favorable effect on HDL-C levels while providing adequate endometrial protection" 5. MPA blunted the HDL benefit of estrogen more than micronized progesterone did, a difference attributed to MPA's partial androgen receptor activity.

Endometrial Protection

All active progestogen arms provided statistically equivalent endometrial protection: adenomatous or atypical hyperplasia occurred in 1% or fewer of women in each progestogen group, versus 34% in the CEE-alone arm. Twelve days of cyclic micronized progesterone was sufficient for full protection.

What PEPI Did Not Show

PEPI was powered for surrogate endpoints (lipids, endometrial histology), not clinical cardiovascular events or cancer outcomes. The trial was three years long and enrolled 875 women, so it cannot answer questions about 10- or 20-year breast cancer risk. The WHI, at 8.5 mean years of follow-up and 16,608 participants, addressed longer-term outcomes but used MPA, not micronized progesterone 8.

Breast Cancer Risk: Micronized Progesterone vs MPA

This question generates more clinical debate than any other in the progestogen comparison.

E3N Cohort Data

The French E3N cohort (N=80,377 women, mean follow-up 8.1 years) found that women using estrogen plus micronized progesterone had no statistically significant increase in breast cancer risk (relative risk 1.00, 95% CI 0.83 to 1.22), while women using estrogen plus synthetic progestins had a relative risk of 1.69 (95% CI 1.50 to 1.91) 15. This is an observational finding and subject to confounding, but it has been replicated in several European cohorts.

Mechanistic Explanation

Micronized progesterone may inhibit breast epithelial cell proliferation in vitro, while MPA has been shown to upregulate growth factors including VEGF in breast tissue in some models 16. These mechanistic differences are consistent with the clinical signal but do not prove causation. A randomized trial powered for breast cancer endpoints with micronized progesterone has not been completed.

NAMS Guideline Position

The 2022 NAMS Hormone Therapy Position Statement states: "There is growing evidence from observational studies and randomized controlled trials that micronized progesterone and dydrogesterone are associated with a lower risk of breast cancer than are synthetic progestins." 14. The statement calls for further randomized evidence but currently recommends micronized progesterone as the preferred progestogen when starting HRT in a woman who has not previously used it.

Choosing the Right Progestogen: A Clinical Decision Framework

The choice of progestogen depends on cost tolerance, route preference, allergy status, side-effect profile, and individual cardiovascular or breast risk. The table below summarizes the comparison.

| Progestogen | Monthly Cost (Generic) | Endometrial Protection | HDL Impact | Systemic Breast-Risk Signal | Sedation | |---|---|---|---|---|---| | Micronized progesterone 100 mg (continuous) | $25 to $60 | Proven (PEPI) | Neutral to favorable | Low (E3N RR 1.00) | Moderate (GABA-A) | | MPA 2.5 mg (continuous) | $10 to $20 | Proven (PEPI, WHI) | Blunts HDL rise | Elevated (WHI HR 1.26) | Low | | Norethindrone acetate 0.5 mg | $30 to $60 | Proven | Mildly adverse | Moderate (observational) | Low | | Mirena IUD | $18 to $23/month (5-yr avg) | Proven (local) | Neutral | Very low (minimal systemic) | None | | Vaginal progesterone gel | $200 to $350 | Probable | Neutral | Low (limited data) | Minimal | | Compounded topical cream | Variable | Not proven | Unknown | Unknown | None |

When to Choose Micronized Progesterone First

A woman starting HRT who has an intact uterus, no peanut allergy, and no compelling reason to use a lower-cost synthetic progestin is a reasonable candidate for generic micronized progesterone. The NAMS 2022 guideline supports this as a first-line choice 14. Women with sleep complaints may find the GABA-A sedative effect of allopregnanolone beneficial rather than burdensome, and bedtime dosing takes advantage of that property.

When MPA May Be Preferred

Women whose insurance formularies exclude micronized progesterone or who face significant out-of-pocket costs may rationally choose MPA at $10 to $20 per month. MPA has 30 years of clinical safety data, proven endometrial protection, and is available at essentially every pharmacy. The cardiovascular signal from WHI applied to older women (mean age 63) starting HRT more than 10 years after menopause; the "timing hypothesis" suggests the risk-benefit calculation differs for women who start HRT within 10 years of menopause or before age 60 17.

When the Mirena IUD Wins

Women who want to avoid any progestogen side effects systemically, who plan to use HRT for more than three years, or who also need contraception benefit most from the Mirena. The upfront cost is the barrier, not the long-term cost. Insertion requires a clinician visit and is associated with short-term cramping in most patients. Expulsion occurs in approximately 3 to 8% of users at five years 10.

Side Effects and Tolerability Comparison

Prometrium Side Effects

Drowsiness and dizziness are the most reported side effects, reported by 24% and 15% of women respectively in the prescribing information studies 4. Headache and breast tenderness occur in roughly 10 to 16% of users. Breakthrough bleeding is common in the first 60 to 90 days of continuous use. Because the sedation is predictable, nighttime dosing eliminates most functional impairment.

MPA Side Effects

MPA is associated with mood changes, bloating, and breast tenderness in a subset of women. Its partial androgen activity may worsen acne and reduce HDL. In the WHI, the MPA arm had a higher rate of myocardial infarction compared with the estrogen-alone arm, though women in both arms were older and many years post-menopause 8.

Norethindrone Acetate Side Effects

Androgenic side effects including acne, hirsutism, and a possible negative effect on libido are the most clinically relevant 9. Some women also report mood changes. It is generally well-tolerated at low HRT doses (0.5 mg to 1 mg daily).

Drug Interactions and Contraindications

Micronized progesterone is metabolized primarily by CYP3A4. Co-administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice in large amounts) may raise progesterone serum levels. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine) may reduce efficacy 4. Prometrium is contraindicated in known or suspected breast cancer, undiagnosed vaginal bleeding, liver dysfunction, and peanut allergy. Women with a history of depression should be monitored, though the allopregnanolone metabolite has anxiolytic properties in many users and worsens mood in a minority 18.

How to Save Money on Prometrium

Generic micronized progesterone from Teva or Perrigo cuts cost by 50 to 70% versus brand Prometrium. GoodRx, RxSaver, and Mark Cuban's Cost Plus Drugs (costplusdrugs.com) list generic micronized progesterone 100 mg x 30 capsules for $18 to $35 as of January 2025. Patients paying out of pocket should request the generic explicitly; some pharmacies default to brand. Mail-order pharmacies through insurance plans typically offer a 90-day supply for the cost of two co-pays, reducing effective monthly cost further. AbbVie's patient assistance program (myAbbVie Assist) may cover Prometrium at no cost for qualifying patients with income below 400% of the federal poverty level 19.

Monitoring on Prometrium

Women using micronized progesterone as part of HRT do not need routine serum progesterone monitoring unless non-adherence or malabsorption is suspected. Endometrial safety is monitored clinically: any unexpected bleeding after the first six months of continuous combined HRT warrants transvaginal ultrasound to measure endometrial thickness and, if the stripe exceeds 4 mm or bleeding is heavy, endometrial biopsy 20. Annual clinical review of HRT indication, dose, and ongoing need aligns with NAMS and ACOG guidance 21.